Triple

T365501
Position Surface form Disambiguated ID Type / Status
Subject Medtronic E7950 entity
Predicate hasDivision P35 FINISHED
Object Minimally Invasive Therapies Group
Minimally Invasive Therapies Group is a Medtronic business unit focused on developing and providing technologies and solutions for minimally invasive surgical and interventional procedures.
E46438 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Minimally Invasive Therapies Group | Statement: [Medtronic, hasDivision, Minimally Invasive Therapies Group]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Minimally Invasive Therapies Group
Context triple: [Medtronic, hasDivision, Minimally Invasive Therapies Group]
  • A. Committee for Advanced Therapies
    The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
  • B. Center for Cellular and Molecular Therapeutics
    The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
  • C. National Institute of Biomedical Imaging and Bioengineering
    The National Institute of Biomedical Imaging and Bioengineering is a U.S. federal research institute that advances the development and application of biomedical imaging and bioengineering technologies to improve health.
  • D. Division of Cancer Treatment and Diagnosis
    The Division of Cancer Treatment and Diagnosis is a branch of the National Cancer Institute that supports the development, evaluation, and clinical testing of new cancer therapies and diagnostic tools.
  • E. Center for Health and Biosciences
    The Center for Health and Biosciences is a research and policy institute focused on health care, biomedical innovation, and related public policy issues.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Minimally Invasive Therapies Group
Triple: [Medtronic, hasDivision, Minimally Invasive Therapies Group]
Generated description
Minimally Invasive Therapies Group is a Medtronic business unit focused on developing and providing technologies and solutions for minimally invasive surgical and interventional procedures.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Minimally Invasive Therapies Group
Target entity description: Minimally Invasive Therapies Group is a Medtronic business unit focused on developing and providing technologies and solutions for minimally invasive surgical and interventional procedures.
  • A. Committee for Advanced Therapies
    The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
  • B. Center for Cellular and Molecular Therapeutics
    The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
  • C. National Institute of Biomedical Imaging and Bioengineering
    The National Institute of Biomedical Imaging and Bioengineering is a U.S. federal research institute that advances the development and application of biomedical imaging and bioengineering technologies to improve health.
  • D. Division of Cancer Treatment and Diagnosis
    The Division of Cancer Treatment and Diagnosis is a branch of the National Cancer Institute that supports the development, evaluation, and clinical testing of new cancer therapies and diagnostic tools.
  • E. Center for Health and Biosciences
    The Center for Health and Biosciences is a research and policy institute focused on health care, biomedical innovation, and related public policy issues.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a2e7e880008190a6ad7e06e5d03007 completed Feb. 28, 2026, 1:04 p.m.
NER Named-entity recognition batch_69a2ebe7d4d0819083daeb7686ae1914 completed Feb. 28, 2026, 1:21 p.m.
NED1 Entity disambiguation (via context triple) batch_69a3e8668b848190b68d19819ac134df completed March 1, 2026, 7:19 a.m.
NEDg Description generation batch_69a3ea5beecc8190b128db693db39e95 completed March 1, 2026, 7:27 a.m.
NED2 Entity disambiguation (via description) batch_69a3eba438548190912d5a4a9c0e6528 completed March 1, 2026, 7:32 a.m.
Created at: Feb. 28, 2026, 1:08 p.m.